Coeptis Therapeutics Holdings CEO David Mehalick's 2023 pay stays at $360K
Coeptis Therapeutics Holdings reports 2023 executive compensation
By ExecPay News
Published: November 14, 2024
Coeptis Therapeutics Holdings reported fiscal year 2023 executive compensation information on November 14, 2024.
In 2023, five executives at Coeptis Therapeutics Holdings received on average a compensation package of $288K, a 9% decrease compared to previous year.
Average pay of disclosed executives at Coeptis Therapeutics Holdings
David Mehalick, Chief Executive Officer, received $360K in total, which is about the same as previous year. 100% of Mehalick's compensation, or $360K, was in salary.
Daniel Yerace, Vice President of Operations, received a compensation package of $360K, which is about the same as previous year. 100% of the compensation package, or $360K, was in salary.
Colleen Delaney, Chief Financial Officer, earned $360K in 2023.
Brian Cogley, Chief Financial Officer, received $208K in 2023.
Christine Sheehy, Chief Financial Officer, earned $151K in 2023, a 33% decrease compared to previous year.
Related executives
David Mehalick
Coeptis Therapeutics Holdings
Chief Executive Officer
Daniel Yerace
Coeptis Therapeutics Holdings
Vice President of Operations
Brian Cogley
Coeptis Therapeutics Holdings
Chief Financial Officer
Colleen Delaney
Coeptis Therapeutics Holdings
Chief Financial Officer
Christine Sheehy
Coeptis Therapeutics Holdings
Chief Financial Officer
You may also like
Source: SEC filing on November 14, 2024.